Recombinant Human CLEC2D protein

中文名： C-型凝集素域家族2成员D(CLEC2D)重组蛋白
别名： CLEC2D；CLAX；LLT1；OCIL；C-type lectin domain family 2 member D

货号: PA1000-640DB

Price： ￥询价

20μg 50μg 100μg ＞100μg

数量：

大包装询价

产品详情

纯度	>85%SDS-PAGE.
种属	Human
靶点	CLEC2D
Uniprot No	Q9UHP7
内毒素	< 0.01EU/μg
表达宿主	E.coli
表达区间	1-154aa
氨基酸序列	MHDSNNVEKDITPSELPANPGCVHSKEHSIKATLIWRLFFLIMFLTIIVC GMVAALSAIRANCHQEPSVCLQAACPESWIGFQRKCFYFSDDTKNWTSSQ RFCDSQDADLAQVESFQELNFLLRYKGPSDHWIGLSREQGQPWKWINGTE WTRQ
预测分子量	43 kDa
蛋白标签	His tag N-Terminus
缓冲液	PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
稳定性 & 储存条件	Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months.
复溶	Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

参考文献

以下是3篇关于CLEC2D重组蛋白的参考文献及其摘要概括：

1. **文献名称**: *CLEC2D functions as an inhibitory receptor on human NK cells*

**作者**: Zhang Y, et al. (2017)

**摘要**: 该研究通过重组CLEC2D蛋白的体外实验，揭示了其在自然杀伤细胞(NK细胞)中作为抑制性受体的作用，发现CLEC2D与配体结合后可下调NK细胞的细胞毒性活性，参与免疫调节。

2. **文献名称**: *Structural basis of CLEC2D recognition by its human cytomegalovirus ligand*

**作者**: Wang X, et al. (2019)

**摘要**: 利用重组CLEC2D蛋白的晶体结构分析，阐明了其与人类巨细胞病毒(HCMV)蛋白UL11的相互作用机制，揭示了病毒通过模拟宿主配体逃逸免疫监视的结构基础。

3. **文献名称**: *CLEC2D modulates T cell-mediated immunity in chronic inflammation*

**作者**: Tanaka S, et al. (2020)

**摘要**: 通过重组CLEC2D蛋白的体外功能实验，证明其在慢性炎症中通过调控T细胞受体信号通路抑制过度免疫反应，为自身免疫疾病治疗提供了潜在靶点。

注：以上文献信息为示例性质，实际引用需以具体论文内容为准。若需精准文献，建议通过PubMed或Web of Science以“CLEC2D recombinant protein”为关键词检索。

背景信息

CLEC2D (C-type lectin domain family 2 member D) is a transmembrane protein belonging to the C-type lectin-like family, which plays roles in immune regulation and cellular interactions. Structurally, it contains an extracellular C-type lectin-like domain (CTLD), a transmembrane region, and a short cytoplasmic tail lacking canonical signaling motifs. Unlike classical C-type lectins, CLEC2D does not bind carbohydrates in a calcium-dependent manner. Instead, it interacts with ligands such as LLT1 (CLEC2D ligand, expressed on activated lymphocytes) and possibly other cell-surface molecules, mediating immune cell communication.

CLEC2D is expressed on natural killer (NK) cells, dendritic cells, and platelets. It functions as a dual-purpose receptor, modulating NK cell cytotoxicity and cytokine production. Interaction with LLT1 can inhibit NK cell activity, suggesting a role in immune tolerance and evasion, particularly in contexts like cancer and viral infections. In platelets, CLEC2D contributes to thrombus formation by binding to podoplanin on endothelial cells.

Recombinant CLEC2D protein, produced via expression systems like *E. coli* or mammalian cells, retains the functional CTLD and is used to study ligand-receptor interactions, signaling mechanisms, and therapeutic targeting. Its applications include blocking CLEC2D-LLT1 interactions to enhance NK-mediated tumor killing or modulating platelet activation pathways. Purification typically involves affinity tags (e.g., His-tag) followed by refolding or chromatography.

Research on CLEC2D highlights its involvement in autoimmune diseases, cancer immunotherapy, and thrombosis, making its recombinant form a valuable tool for mechanistic studies and drug development. However, its full ligand repertoire and downstream signaling pathways remain partially characterized, warranting further investigation.